Study 01Completed
Adult mild TBI
Biomarker presence, TBI specificity and time-course after injury across Finnish central hospitals.
Traumatic brain injury · Point-of-care diagnostics
Bring clarity
to brain injury.
ProbTBI™ is a non-invasive, point-of-care test that detects concussion and traumatic brain injury from a single body-fluid sample — read in minutes, as simply as a pregnancy test.
- 3studies
- Completed in Finland
- 151
- Participants across the studies
- 2014
- Founded in Turku, Finland
ProbTBI™
Cassette · LF-02SAMPLE PT-0241 · 11:24
Negative
No biomarker detected — all clear.
- Biomarker
- 0.4 ng/mL
- Threshold
- 5.0 ng/mL
- Read time
- 11 min
- Operator
- A. Harel
Funded by
Business FinlandHorizon 2020US Dept. of Defense
Clinical & research partners
Turku University HospitalBioTurku
The unmet need
Brain injury is still hard to measure.
TBI diagnosis and treatment are unmet needs in medicine — today there is no non-invasive, power-free, point-of-care tool to assess the extent and severity of a traumatic brain injury. Nearly 5 million US emergency visits each year involve head injury, and up to 90% are mild TBI, many undiagnosed.
- 5M
- US emergency-department visits for head injury each year
- ~90%
- Of those head injuries are mild TBI — and often go undiagnosed
- 0
- Non-invasive, power-free point-of-care tests for TBI exist today
How ProbTBI works
From injury to answer.
No imaging, no central lab, no specialist. ProbTBI brings an objective biomarker result to wherever the injury happens.
- 01
Collect
A non-invasive body-fluid sample at the point of injury — no needle, no scanner.
- 02
Detect
A proprietary glycan biomarker binds on a lateral-flow cassette.
- 03
Read
A clear positive or negative appears in minutes — no instrument.
- 04
Act
Positive indicates injury — escalate care. Negative is all clear.
ProbTBI™ rapid test
A lab result, at the point of injury.
No imaging. No central lab. No waiting. ProbTBI puts an objective, biomarker-based answer in the hands of first responders, emergency teams, sports physicians and GPs.
- Non-invasive sample
- Body-fluid sample — comfortable for adults and children alike.
- Result in minutes
- Point-of-care read at the bedside or on the sideline.
- Simple to interpret
- Positive or negative — no training, no instrument required.
- Built on IP
- Protected by a portfolio of 7 patents. Medicortex name trademarked.
Reading the result
Lateral-flow cassetteNo biomarker
Negative
No brain injury detected.
Biomarker present
Positive
Brain injury indicated — escalate care.
As easy to interpret as a pregnancy test — positive or negative, no instrument required.
Clinical evidence
Evaluated across three hospital studies.
Study 02Completed
Extended detection
Accelerated recruitment at Turku University Hospital; comparison to orthopedic and healthy controls.
Study 03Completed
Children & adolescents
Large paediatric cohort with suspected mild TBI — validating the test in young patients.
“We have the opportunity to develop a portable, non-invasive test for quick detection of mild TBI and concussion — and thereby help patients and families who so desperately need it.”
Frequently asked
How is the sample collected?+
ProbTBI uses a non-invasive body-fluid sample taken at the point of care — no blood draw, no imaging, suitable for adults and children.
How do I read the result?+
The cassette shows a positive or negative result within minutes, interpreted as simply as a pregnancy test. Positive indicates the presence of brain injury; negative means no injury detected.
Where is Medicortex based?+
Medicortex operates its R&D from Pharma City, Turku, Finland — within Turku Science Park. Medicortex International AB (publ) is registered in Stockholm, Sweden.
What is the listing status?+
The reverse takeover completed on 30 June 2026: NGM's listing conditions were satisfied, the company was renamed from NOSIUM AB (publ) to Medicortex International AB (publ), and Dr. Adrian Harel was appointed CEO. The company acquired 89.9% of Medicortex Finland Oyj and its shares trade on NGM Growth Market under the ticker MEDFIN.
Corporate governance
Board, management & ownership.
Board of Directors
Anna Tenstam
Chair · Independent
MSc (Uppsala) and MBA (IMD Lausanne); 30+ years of leadership in pharmaceutical, medical-device and medical-aesthetics companies, with global CEO and chairman roles.
Dr. Adrian Harel
Founder & CEO · Board member
PhD in Neurobiology (Weizmann Institute) and MBA (University of Haifa); deep drug-development, GMP and manufacturing experience. Former CEO of BrainStorm Cell Therapeutics.
Nils Grönberg
Board member · Independent
30+ years in leadership across foundations and companies in the Turku region, with expertise in sales management, networks, investing and fundraising.
Ville Ranta-Panula
Board member · Independent
Globally networked drug- and business-development professional; currently Chief Commercial Officer at CRST Oy and a certified board member.
Jesper Yrwing
Board member
MSc in Economics (International Business), European Business School London; experienced business controller and CFO. Serves as the group's operational CFO.
Management team
Dr. Adrian Harel
Chief Executive Officer
Founder; a track record leading early-stage biotechnology companies through R&D and GMP.
Jesper Yrwing
Chief Financial Officer
Long experience as business controller and CFO. Board member and the group's operational CFO.
Dr. Lasse Välimaa
Chief Scientific Officer
PhD in Molecular Biotechnology & Diagnostics; Head of R&D since 2015, leading assay and detection development.
Pihla Miettinen
Chief Operating Officer
MSc in Human Neuroscience (Turku); oversees procurement, supplier relations, HR and public relations.
Largest shareholders
Aligned for the long term.
The founder and board hold a significant stake, aligning leadership with shareholder value. The full register is maintained at Euroclear.
- Dr. Adrian HarelFounder, CEO & board member9,435,650
- Anna TenstamChair (independent)7,000
- Other shareholders & free floatInstitutional & retail investorsBroadly held
Through the transaction the group acquired 89.9% of Medicortex Finland Oyj. Per-shareholder holdings shown here are indicative — refer to the company's information memorandum and the Euroclear register for exact figures.
Portfolio holdings
The listed vehicle's existing holdings.
Medicortex International AB (publ) — formerly NOSIUM AB (publ) — carries a portfolio of holdings from its venture-builder history. Combined book value ≈ 14.4 MSEK. Figures per company filings.
Co-properties
Listed minority holding
- Capital
- 5.49%
- Votes
- 5.13%
- Book value
- 8.8 MSEK
Invest Riddarholmen 1802
Wholly-owned subsidiary
- Capital
- 100%
- Votes
- 100%
- Book value
- 5.1 MSEK
NOSIUM Consulting
Wholly-owned subsidiary
- Capital
- 100%
- Votes
- 100%
- Book value
- 0.32 MSEK
Dividend Sweden AB (publ)
Listed minority holding
- Capital
- 0.39%
- Votes
- 0.37%
- Book value
- 0.15 MSEK
News & events
Latest from Medicortex.
20 Aug 2026 · Investor
A new chapter — from scientific innovation to commercial execution
Letter from the Chairman outlining the shift in focus after the reverse acquisition, the name change and continued listing on NGM Growth Market (MEDFIN).
Read more11 Aug 2026 · Investor
Shareholder update — August 2026
A summer recap: the 30 June reverse takeover of Medicortex Finland Oyj met all of NGM's conditions and the listed company now operates as Medicortex International AB (publ).
Read more1 Jul 2026 · Listing
Observation status removed on NGM
NGM removed the observation status for the Medicortex International share following completion of the reverse takeover.
Read more30 Jun 2026 · Listing
Reverse takeover completed — Adrian Harel appointed CEO
The acquisition of Medicortex Finland is complete, NGM's conditions are satisfied, and NOSIUM AB (publ) is renamed Medicortex International AB (publ).
Read more
Heading towards a solution
Invest in the clarity patients deserve.
Medicortex International AB (publ) completed its reverse takeover on 30 June 2026 and trades on NGM Growth Market under MEDFIN. The group has raised EUR 8.4M, including three US Department of Defense grants, holds 7 patents, and is advancing ProbTBI toward a TBI-diagnostics market forecast at USD 3.3bn by 2029. Certified Adviser: Nordic Certified Adviser AB.
- MEDFIN
- NGM Growth Market ticker · Medicortex International AB (publ)
- 89.9%
- of Medicortex Finland Oyj acquired by the group
- 3 / 3
- Clinical studies complete